Apotex launches Axitinib Tablets in the U.S., the first generic version of INLYTA®

Wait 5 sec.

TORONTO, Nov. 16, 2026 /PRNewswire/ -- Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version on INLYTA ®, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure...